Effect-site Concentration of Remifentanil for Smooth Induction With Desflurane

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02379715

Enrollment

Registered

2015-03-05

Start date

2014-12-31

Completion date

2015-05-31

Last updated

2020-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia

Keywords

Remifentanil, smooth induction, desflurane

Brief summary

Desflurane is a halogenated ether with low solubility, giving rapid induction and emergence from anesthesia This character is suitable for Volatile Induction and Maintenance Anesthesia (VIMA). But desflurane can cause airway irritation when it used as a sole induction agent to adult or children, so there were many studies about reducing the airway reflex combined with desflurane. Remifentanil is a short acting opioid and is quickly hydrolyzed by nonspecific esterase in the plasma and multiorgan. Several studies suggest the optimal dose of remifentanil for reducing airway reflex or cardiovascular response for intubation combined with desflurane. But these studies were under 1 Minimal Alveolar Concentration (MAC) of desflurane and this point could be a limitation because desflurane concentration over 1 MAC increase airway irritation significantly. This study this study was designed to determine a median effective effect-site concentration (EC50) of remifentanil to prevent airway irritation during desflurane anesthesia over 1 MAC.

Interventions

DRUGRemifentanil

DRUGDesflurane

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

19 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* patients for surgery requiring general anesthesia * American Society of Anesthesiologists(ASA) classification I, II

Exclusion criteria

* history of gastroesophageal reflux, High grade obesity, Predicted difficult airway, Asthma, Chronic obstructive pulmonary disease(COPD), Upper respiratory infection (URI) within 3 weeks

Design outcomes

Primary

Measure	Time frame	Description
Fail or success for induction with desflurane	After loss of consciousness, 5 seconds	Failure for induction with desflurane is defined if there is a cough, laryngospasm, hypoxia or any refusal movement of patient.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026